Loading...
XNASCRDL
Market cap102mUSD
Dec 24, Last price  
1.26USD
1D
0.80%
1Q
-40.57%
IPO
-66.62%
Name

Cardiol Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:CRDL chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
33.20%
Rev. gr., 5y
%
Revenues
0k
000078,76000
Net income
-28m
L-9.06%
-1,660,926-15,893,735-13,684,023-20,640,935-31,638,244-30,930,647-28,128,291
CFO
0k
P
-1,292,194-10,894,005-11,380,080-9,185,430-23,550,779-27,220,3450
Earnings
Mar 31, 2025

Profile

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce cardiovascular and respiratory events in patients hospitalized with COVID-19, as well as to evaluate the efficacy and safety of CardiolRx in acute myocarditis. The company is also developing subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation in the heart that is related with the development and progression of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.
URL
https://www.cardiolrx.com/
IPO date
Dec 20, 2018
Employees
Domiciled in
CA
Incorporated in
CA

Valuation

Title
CAD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑12
Income
Revenues
79
 
Cost of revenue
30,034
41,556
38,744
Unusual Expense (Income)
NOPBT
(30,034)
(41,556)
(38,665)
NOPBT Margin
Operating Taxes
(10,241)
(6,914)
Tax Rate
NOPAT
(30,034)
(31,315)
(31,750)
Net income
(28,128)
-9.06%
(30,931)
-2.24%
(31,638)
53.28%
Dividends
Dividend yield
Proceeds from repurchase of equity
84,084
BB yield
-83.49%
Debt
Debt current
16
50
45
Long-term debt
333
95
190
Deferred revenue
Other long-term liabilities
Net debt
(34,583)
(59,324)
(83,664)
Cash flow
Cash from operating activities
(27,220)
(23,551)
CAPEX
(75)
(13)
Cash from investing activities
(75)
(13)
Cash from financing activities
(54)
93,438
FCF
(30,075)
(31,254)
(31,627)
Balance
Cash
34,932
59,470
83,899
Long term investments
Excess cash
34,932
59,470
83,895
Stockholders' equity
9,461
36,615
63,578
Invested Capital
18,960
15,660
12,778
ROIC
ROCE
EV
Common stock shares outstanding
64,463
62,506
43,223
Price
1.10
59.42%
0.69
-70.39%
2.33
-16.19%
Market cap
70,909
64.41%
43,129
-57.17%
100,709
21.33%
EV
36,326
(16,195)
17,045
EBITDA
(30,034)
(41,336)
(38,444)
EV/EBITDA
0.39
Interest
Interest/NOPBT